Last reviewed · How we verify
Postoperative pain — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Journavx | SUZETRIGINE | Vertex Pharms Inc | Sodium Channel Blocker [EPC] | 2025-01-01 | ||
| Sufenta Preservative Free | SUFENTANIL | Rising | Opioid Agonist | Mu-type opioid receptor | 1984-01-01 | |
| Sulfentanyl | Sulfentanyl | Shenzhen Third People's Hospital | Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor | |||
| Sulfentanil | Sulfentanil | Henan Provincial People's Hospital | Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Henan Provincial People's Hospital · 1 drug in Postoperative pain
- Rising · 1 drug in Postoperative pain
- Shenzhen Third People's Hospital · 1 drug in Postoperative pain
- Vertex Pharms Inc · 1 drug in Postoperative pain
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Postoperative pain:
- Postoperative pain treatment updates — RSS
- Postoperative pain treatment updates — Atom
- Postoperative pain treatment updates — JSON
Cite this brief
Drug Landscape (2026). Postoperative pain — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/postoperative-pain. Accessed 2026-06-10.
Related
- Postoperative pain full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing